Millions earmarked to boost research into new life-saving products to address the global rise of drug-resistant bacteria

07 June 2018

The UK Government’s Global Antimicrobial Resistance Innovation Fund (GAMRIF) and the Bill & Melinda Gates Foundation (BMGF) have joined the CARB-X partnership to support scientific research around the world to develop new vaccines, preventatives, and other products against drug-resistant bacterial infections, particularly among vulnerable populations in low- and middle-income countries.

The UK Government is committing up to £20 million, and the Bill & Melinda Gates Foundation up to US$25 million, to CARB-X over the next three years. Combined with existing funding commitments from Wellcome Trust and the US Government (BARDA and NIAID), CARB-X now has more than $500 million to invest in antibacterial development.

More information available at CARB-X

CARB-X still welcomes applications from around the world for funding and support for the early development of antibiotics, diagnostics, vaccines, devices and other products to combat the most serious drug-resistant bacteria. Expressions of interest must be submitted online between 1 June and 8 June. Details about application are available at